Prognostic Features of Anti-Cancer Drugs Response in Resected/Unresected Primary Non-Small Cell Lung Cancer: A Retrospective Cohort Study

07 Jul 20264 min read0 viewsVerified Feed

GIST (Key Takeaways)

Abstract Aim: Low chemotherapy response is a major risk factor for early mortality in cancer patients; it is one of the biggest challenges in cancer treatment. Main aim of this study is to identify chemotherapy non-responder, prognostic significance of pre-chemotherapy baseline variables in survival, distinguish most effective anti-cancer drug classes and formulation.
Methods: In this multi-center retrospective cohort (n=2459) patients deceased with NSCLC and received anti-cancer drugs were included for analyses. To identify chemotherapy non-responder, patient population was divided into three sub-groups based on chemotherapy prescription frequency [1-15] as group-A, [16-30] as group-B, and [[≥]31] as group-C.
Multivariate analysis was performed to identify risk of 1-year mortality in these groups. To prognose chemotherapy response in resected and unresected NSCLC patients, 0-7 days pre-chemotherapy white blood cell (WBC) count total five-ranges were compared as per overall survival in abnormal Vs normal WBC counts.
Results: Post-stratification in group-A there were (n=1289) patients, in group-B (n=648) patients, and in group-C (n=522) patients.

Clinical Editorial

medRxiv (Clinical Preprints) published a clinical update in Research Highlights on 07 Jul 2026.

The item focuses on Prognostic Features of Anti-Cancer Drugs Response in Resected/Unresected Primary Non-Small Cell Lung Cancer: A Retrospective Cohort Study.

Review the original article for the full source wording and details.